Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 2008Seminars in Thrombosis and HemostasisOpen Access

Development of New Anticoagulants: Present and Future

View Full Paper
Ask AI
Bookmark
Share

Key result

This overview describes the development and recent study results of new synthetic indirect and direct factor Xa inhibitors and direct thrombin inhibitors for thromboembolism.

Design

Review

Authors

JHJob HarenbergHeidelberg University

Discussion

Loading...

Member takes

Implication

Summarizes emerging DOAC options for thromboembolism; leaves open optimal positioning and long-term safety in routine practice.

Structured PICO

I
Intervention
New anticoagulants including synthetic indirect and direct factor Xa inhibitors and direct thrombin inhibitors (e.g., rivaroxaban, apixaban, idraparinux, ximelagatran, dabigatran)

This review summarizes the development and recent study results of new direct oral anticoagulants aimed at improving the safety and efficacy profile over traditional therapies.

Cite This Study

Job Harenberg (2008) conducted a review in Venous and arterial thromboembolism. New anticoagulants (factor Xa inhibitors and direct thrombin inhibitors) was evaluated. This overview describes the development and recent study results of new synthetic indirect and direct factor Xa inhibitors and direct thrombin inhibitors for thromboembolism.

synapsesocial.com/papers/6a89b163d89205768aeb42ffhttps://doi.org/10.1055/s-0029-1145260

Topics

Anticoagulation in AF
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pharmacology and Clinical Potential of Direct Thrombin Inhibitors2005 · 23 citations
  2. 2Animal Models of Thrombosis Help Predict the Human Therapeutic Concentration of PRT54021, a Potent Oral Factor Xa Inhibitor.2006 · 22 citations
  3. 3Pharmacokinetics of Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Male Subjects: Pharmacokinetic Model Development for Phase 2/3 Simulation of Exposure2006 · 31 citations
  4. 4A critical reappraisal of the bleeding time.1990 · 591 citations
  5. 5Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases2006 · 106 citations